1-3 of 3
Patricia J Keller
Close
Sort by
Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Srdan Verstovsek, Mohamed E Salama, John Mascarenhas, Moshe Talpaz, Ruben A. Mesa, Alessandro Vannucchi, Raajit Rampal, Stephen T. Oh, Horatiu Olteanu, April Chiu, Dong Chen, Curtis A. Hanson, Natalia Curto-Garcia, Pietro Taverna, Jike Cui, Oksana Zavidij, Zehua Chen, Gozde Colak, Sergey Efuni, Patricia J Keller, Patrick Trojer, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 2568.
https://doi.org/10.1182/blood-2021-152267
Published: 2021
Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Jennifer A Mertz, PhD, Patricia J Keller, PhD, Rosana D Meyer, MD, Oksana Zavidij, PhD, Jike Cui, PhD, Jean-Jacques Kiladjian, MD PhD, Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Moshe Talpaz, MD, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Ruben Mesa, MD, John Mascarenhas, MD, Adrian Senderowicz, MD, Gozde Colak, PhD, James Shao, MS, Katarina Luptakova, MD, Jeffrey S Humphrey, MD, Jing Wang, PhD, Patrick Trojer, PhD, Mohamed E Salama, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-138752
Published: 2020
Journal Articles

Rac GTPases Are Potential Therapeutic Targets in p210-BCR-ABL-Induced Myeloproliferative Disease (MPD).

Emily K. Thomas, PhD, Jose A. Cancelas, MD, PhD, Heedon Chae, PhD, Adrienne D. Cox, PhD, Patricia J. Keller, PhD, Danilo Perrotti, MD, PhD, Paolo Neviani, Brian J. Druker, MD, Yi Zheng, PhD, Chad E. Harris, David A. Williams, MD
Journal: Blood
Blood (2007) 110 (11): 465.
https://doi.org/10.1182/blood.V110.11.465.465
Published: 2007